The double-blind, placebo-controlled single ascending dose (SAD) trial evaluated the safety and pharmacokinetics of four doses of FV-100 in five cohorts of healthy volunteers (100, 200, 400, and
This second tranche of $15 million was funded by existing investors – Mediphase Venture Partners, CMEA Ventures, Fidelity Biosciences, Flagship Ventures and Skyline Ventures. Guy Macdonald, president and
Defend is a randomized, placebo controlled Phase III trial designed to enroll approximately 240 adult patients, age 18 to 35, with newly diagnosed autoimmune type 1 diabetes. Defend
The settlement is expected to close by September 5, 2008. UCB will pay Eurand a total of $35 million, of which $25 million will be paid at closing,
This finding is from a subanalysis designed and completed following the closure of the five-year treating to new targets (TNT) study in patients with existing coronary heart disease.
This is said to be the first application submitted by Scolr based on its controlled delivery technology platform. Pseudoephedrine is an active ingredient in Allegra D, Sudafed PSE,
Under the agreement, Covance will acquire Lilly’s 450-acre early drug development campus in Greenfield, Indiana for $50 million and will offer employment to about 260 Lilly employees. In
The Alnylam product candidate, ALN-VSP, is being developed as a treatment for liver cancers and potentially other solid tumors. ALN-VSP comprises small interfering RNA (siRNA) molecules delivered systemically
The open-label, multi-dose, dose-escalation Phase I clinical trial is expected to enroll up to 46 patients with selected advanced or recurrent solid tumors. This trial is designed to
According to the company, DXLr120 significantly improves antibodies binding to CD20, the target for non Hodgkin’s lymphoma and rheumatoid arthritis and joins InNexus’s DXL625 (CD20). DXL625, developed with
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.